![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
Lista de categorías
AlcoholismoAlzheimer Y ParkinsonAnalgésicosAntialérgicasAntibióticosAnticonceptivosAnticonvulsivosAntidepresivosAntifúngicosAntiinflamatoriosAntiparasitariosAntiviralesArtritisAsmaCirugíaColesterolCuidados De La PielCuidados De Los OjosCáncerDiabetesDisfunción EréctilDiuréticosEnfermedad CardiovascularEnfermedades GastrointestinalesEnfermedades GenitourinariasEnfermedades NeurológicasMedicamentos V I HMigrañasOsteoporosisPresión ArterialPérdida De PesoRelajantes MuscularesSalud FemeninaSalud MasculinaTracto RespiratorioTrastornos Mentales 17 May 2012 06:52:05
טבע: יעדי 2015 אופטימיים מדי? : 2015 ? ר ר ר Lexapro, Avapro Avalide ר ר , , ר . ר ר Lexapro ר ר 2.5 ר ר, ...14 May 2012 10:02:22
Teva Pharmaceuticals' Disappointing ResultsTeva Pharmaceuticals' Disappointing Results Seeking Alpha The company recently announced that it has started selling Irbesartan and irbesarten-hydrochlorothiazide tablets, a generic version of Sanofi-Aventis' high blood pressure drugs, Avapro and Avalide tablets. Teva also has exclusivity to market the ...
07 May 2012 04:33:53
Top global pharma cos post sales growth of just 3.4%, but net profit up by ...Top global pharma cos post sales growth of just 3.4%, but net profit up by ... pharmabiz.com Similarly, Aciphex Pariet of J&J , NeoRecormon Epogin of Roche and Avapro Avalide of Bristol-Myers lost blockbuster status in 2011. Besides, Lipitor and Seretide Advair, few important blockbuster products like MabThera Rituxan (Roche), ...
05 May 2012 00:19:38
Earnings Scorecard: Bristol-Myers - Analyst BlogEarnings Scorecard: Bristol-Myers - Analyst Blog NASDAQ Revenues were just shy of the Zacks Consensus Estimate of $5.26 billion, mainly due to lower sales of Plavix and Avapro Avalide . US net sales in the quarter climbed 6% to $3.5 billion. Sales in international markets increased 2% to $1.8 billion.
30 Apr 2012 15:52:22
Sanofi Beats on EPS, View Backed The Star-Ledger - NJ.com Sanofi Beats on EPS, View Backed Zacks.com Aprovel Avapro Karvea Avalide revenues declined 18.1% to 404 million due to increased generic competition. The product lost its exclusivity on March 30, 2012. Lovenox, Ambien CR and Taxotere, performed disappointingly due to generic competition in the ... Strong first quarter for Sanofi, rest of year will be tougher27 Apr 2012 09:08:23
Earnings Beat at Bristol-Myers - Analyst Blog Dividend.com Earnings Beat at Bristol-Myers - Analyst Blog NASDAQ Revenues were just shy of the Zacks Consensus Estimate of $5.26 billion, mainly due to lower sales of Plavix and Avapro Avalide . US net sales in the quarter climbed 6% to $3.5 billion. Sales in international markets increased 2% to $1.8 billion. Bristol-Myers Squibb Delivers a Solid First Quarter with Strong Operating ... Bristol-Myers 1Q profit up 12 pct. as sales rise Bristol-Myers Net Rises 12% on High Cancer Drug Sales24 Apr 2012 20:43:13
Bristol-Myers Squibb: Earnings PreviewBristol-Myers Squibb: Earnings Preview Citybizlist (press release) Net sales in the final quarter of 2011 quarter climbed 7% to $5.45 billion. Revenues were just shy of the Zacks Consensus Estimate of $5.48 billion mainly due to lower sales of Plavix and Avapro Avalide . READ FULL ARTICLE HERE.
|
|
Choose Your language:
Site search
Testimonios de nuestros clientes
Debo excusarme - pensaba que ustedes querian engañarme. Pero la demora era causada por un error. Recibí el encargo el jueves 8 de junio, y el otro el sábado 10 de junio. ¡ Tardo casi un mes pero fue a causa de un error en los datos de envio! Muchas gracias. - Curt
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Bestsellers|Nuestra política|F.A.Q.|Testimonios de nuestros clientes|Contacto|Sitemap |
|
|
|
|
| |